Wed 18 Aug, 2010
The New York Times published a story about the benefits of open data for medical research. A collaboration begun in 2003 brought together scientists from the public and private sector to find the biological markers that show the progression of Alzheimer’s disease.
The project sought to raise money, conduct research — and to share the research data — with the public immediately. No scientist or drug company owns the data, although private companies will have opportunities to profit from their investments in the project as new drugs or imaging tests are developed as a result of the research findings. By sharing the data, scientists in one lab have access to the findings of other scientists. The effort involved to find the biomarkers is enormous, so collaboration encouraged helped speed discovery. Version:1.0 Companies as well as academic researchers are using the data. There have been more than 3,200 downloads of the entire massive data set and almost a million downloads of the data sets containing images from brain scans.
This might signal a change in how research is funded and conducted, at least in biomedical research, although most scientists and companies are likely to remain cautious. As Dr. John Q. Trojanowski, a scientist from the University of Pennsylvania said, “It’s not science the way most of us have practiced it in our careers.”